153 related articles for article (PubMed ID: 20701084)
1. BRCA1 expression in triple negative sporadic breast cancers.
Galizia E; Giorgetti G; Piccinini G; Santinelli A; Loretelli C; Bianchi F; Gagliardini D; Carbonari G; Pisa E; Belvederesi L; Bracci R; Ferretti C; Corradini F; Cellerino R
Anal Quant Cytol Histol; 2010 Feb; 32(1):24-9. PubMed ID: 20701084
[TBL] [Abstract][Full Text] [Related]
2. CpG island methylation profile of estrogen receptor alpha in Iranian females with triple negative or non-triple negative breast cancer: new marker of poor prognosis.
Ramezani F; Salami S; Omrani MD; Maleki D
Asian Pac J Cancer Prev; 2012; 13(2):451-7. PubMed ID: 22524805
[TBL] [Abstract][Full Text] [Related]
3. Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients.
Fumagalli C; Pruneri G; Possanzini P; Manzotti M; Barile M; Feroce I; Colleoni M; Bonanni B; Maisonneuve P; Radice P; Viale G; Barberis M
Breast Cancer Res Treat; 2012 Jul; 134(1):131-7. PubMed ID: 22228432
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
Huang R; Ding P; Yang F
Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
[TBL] [Abstract][Full Text] [Related]
5. BRCA1-methylated sporadic breast cancers are BRCA-like in showing a basal phenotype and absence of ER expression.
Bal A; Verma S; Joshi K; Singla A; Thakur R; Arora S; Singh G
Virchows Arch; 2012 Sep; 461(3):305-12. PubMed ID: 22820987
[TBL] [Abstract][Full Text] [Related]
6. Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer.
Toffoli S; Bar I; Abdel-Sater F; Delrée P; Hilbert P; Cavallin F; Moreau F; Van Criekinge W; Lacroix-Triki M; Campone M; Martin AL; Roché H; Machiels JP; Carrasco J; Canon JL
Breast Cancer Res; 2014 Nov; 16(6):466. PubMed ID: 25416589
[TBL] [Abstract][Full Text] [Related]
7. Frequent epigenetic inactivation of the receptor tyrosine kinase EphA5 by promoter methylation in human breast cancer.
Fu DY; Wang ZM; Wang BL; Chen L; Yang WT; Shen ZZ; Huang W; Shao ZM
Hum Pathol; 2010 Jan; 41(1):48-58. PubMed ID: 19733895
[TBL] [Abstract][Full Text] [Related]
8. BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from tissue microarrays.
Bane AL; Beck JC; Bleiweiss I; Buys SS; Catalano E; Daly MB; Giles G; Godwin AK; Hibshoosh H; Hopper JL; John EM; Layfield L; Longacre T; Miron A; Senie R; Southey MC; West DW; Whittemore AS; Wu H; Andrulis IL; O'Malley FP
Am J Surg Pathol; 2007 Jan; 31(1):121-8. PubMed ID: 17197928
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 Promoter Methylation and Expression - Associations with ER+, PR+ and HER2+ Subtypes of Breast Carcinoma.
Kumar M; Sahu RK; Goyal A; Sharma S; Kaur N; Mehrotra R; Singh UR; Hedau S
Asian Pac J Cancer Prev; 2017 Dec; 18(12):3293-3299. PubMed ID: 29286222
[TBL] [Abstract][Full Text] [Related]
10. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic Inactivation of BRCA1 Through Promoter Hypermethylation and Its Clinical Importance in Triple-Negative Breast Cancer.
Yamashita N; Tokunaga E; Kitao H; Hitchins M; Inoue Y; Tanaka K; Hisamatsu Y; Taketani K; Akiyoshi S; Okada S; Oda Y; Saeki H; Oki E; Maehara Y
Clin Breast Cancer; 2015 Dec; 15(6):498-504. PubMed ID: 26195437
[TBL] [Abstract][Full Text] [Related]
12. Epigenetic inactivation of BRCA1 is associated with aberrant expression of CTCF and DNA methyltransferase (DNMT3B) in some sporadic breast tumours.
Butcher DT; Rodenhiser DI
Eur J Cancer; 2007 Jan; 43(1):210-9. PubMed ID: 17071074
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between "triple-negative" and non-"triple-negative" tumors.
Tawfik K; Kimler BF; Davis MK; Fan F; Tawfik O
Hum Pathol; 2012 Jan; 43(1):23-30. PubMed ID: 21777944
[TBL] [Abstract][Full Text] [Related]
14. Expression of BRCA1 protein in breast cancer and its prognostic significance.
Rakha EA; El-Sheikh SE; Kandil MA; El-Sayed ME; Green AR; Ellis IO
Hum Pathol; 2008 Jun; 39(6):857-65. PubMed ID: 18400253
[TBL] [Abstract][Full Text] [Related]
15. Correlation between CpG methylation profiles and hormone receptor status in breast cancers.
Feng W; Shen L; Wen S; Rosen DG; Jelinek J; Hu X; Huan S; Huang M; Liu J; Sahin AA; Hunt KK; Bast RC; Shen Y; Issa JP; Yu Y
Breast Cancer Res; 2007; 9(4):R57. PubMed ID: 17764565
[TBL] [Abstract][Full Text] [Related]
16. Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers.
Fkih M'hamed I; Privat M; Ponelle F; Penault-Llorca F; Kenani A; Bignon YJ
Cell Oncol (Dordr); 2015 Dec; 38(6):433-42. PubMed ID: 26392359
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation and post-transcriptional mechanisms for reduced BRCA1 immunoreactivity in sporadic human breast cancers.
Miyamoto K; Fukutomi T; Asada K; Wakazono K; Tsuda H; Asahara T; Sugimura T; Ushijima T
Jpn J Clin Oncol; 2002 Mar; 32(3):79-84. PubMed ID: 11956301
[TBL] [Abstract][Full Text] [Related]
18. Aberrant methylation of RASSF1A is associated with poor survival in Tunisian breast cancer patients.
Karray-Chouayekh S; Trifa F; Khabir A; Boujelbane N; Sellami-Boudawara T; Daoud J; Frikha M; Jlidi R; Gargouri A; Mokdad-Gargouri R
J Cancer Res Clin Oncol; 2010 Feb; 136(2):203-10. PubMed ID: 19657672
[TBL] [Abstract][Full Text] [Related]
19. Outcome after breast conservation treatment with radiation for women with triple-negative early-stage invasive breast carcinoma.
Solin LJ; Hwang WT; Vapiwala N
Clin Breast Cancer; 2009 May; 9(2):96-100. PubMed ID: 19433390
[TBL] [Abstract][Full Text] [Related]
20. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]